How much does Kisunla (Donanemab Injection) Cost& price without insurance in China?
Kisunla® is the commercial brand name of Donanemab Injection, a humanized monoclonal antibody developed by Eli Lilly and Company. It targets and clears accumulated amyloid-beta plaques in the brain to slow the progression of Alzheimer’s disease.
Main Indications
Treatment of adult patients with early-stage Alzheimer’s disease (mild cognitive impairment or mild dementia stage) with confirmed amyloid pathology.
Common Side Effects
Common mild adverse reactions: Infusion-related reactions, headache, and dizziness.
Laboratory abnormalities: Amyloid-related imaging abnormalities (ARIA), including ARIA-edema and ARIA-hemosiderin deposition.
Severe but uncommon risks: Severe intracranial hemorrhage, severe hypersensitivity reactions, and ARIA with clinical symptoms.
Approval Status in China
Kisunla® (Donanemab Injection, 350mg/20mL per vial) was officially approved for marketing in China in 2025. It is currently a prescription drug included in China’s Category B medical insurance.
Buy Kisunla (Donanemab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
